top of page
Rinnit logo – modern health products and health news

Understanding VLCAD Deficiency: Causes, Symptoms, and Management

Oct 11
6 min read

Updated: 2 days ago

Medically reviewed by Dr. Baraa Alnahhal, MD · Last reviewed: October 2026

Very Long-Chain Acyl-CoA Dehydrogenase (VLCAD) deficiency is a rare genetic metabolic disorder that prevents the body from converting certain fats into energy. [1] Primarily identified through newborn screening, it requires lifelong management focused on avoiding fasting and following a specialized diet. [1] While severity varies, early intervention and consistent care allow most individuals to lead full, healthy lives.

Quick Answer

VLCAD deficiency is a metabolic condition caused by a lack of the enzyme needed to break down very long-chain fatty acids, so the body struggles to make energy, especially during illness, exercise or fasting. [1] Management includes a low-fat, high-carbohydrate diet, frequent meals and supplements like MCT oil. Early detection helps prevent heart, liver and muscle complications.

What the research says

  • Triheptanoin improved heart measures compared with standard MCT oil in a small trial. In a double-blind randomized trial of 32 people with long-chain fatty acid oxidation disorders (including VLCAD deficiency), the triheptanoin group raised left ventricular ejection fraction by 7.4% and had a 20% drop in resting left ventricular wall mass, and needed a lower heart rate for the same exercise workload than the trioctanoin (standard MCT) group, with no difference in rhabdomyolysis (Gillingham et al., J Inherit Metab Dis, 2017) [2].

  • A positive newborn screen needs confirmation. Among 693 unrelated people tested after a positive newborn screen for VLCAD deficiency, the most frequent finding was a single ACADVL variant (57%), consistent with carrier status, which is why follow-up enzyme and genetic testing matter (Miller et al., Mol Genet Metab, 2015) [3].

  • Screening and enzyme results help predict severity. In a Swedish cohort of 22 patients (20 diagnosed through newborn screening), clinical severity correlated with residual enzyme activity and newborn screening scores, and most patients found through screening had less severe disease than those diagnosed after symptoms appeared (Olsson et al., JIMD Rep, 2022) [4].

What is VLCAD Deficiency?

Very Long-Chain Acyl-CoA Dehydrogenase (VLCAD) deficiency is a rare inherited disorder that disrupts the body's ability to metabolize specific fats for fuel. [1] Under normal conditions, the body breaks down long-chain fatty acids to create energy when glucose levels are low. In individuals with VLCAD, a genetic mutation prevents the production of the necessary enzyme for this conversion. Consequently, the body may experience energy shortages during times of high demand, such as between meals or during physical activity. [1]

The condition is classified as an autosomal recessive disorder, meaning a child must inherit two copies of the mutated gene—one from each parent—to develop the deficiency. [1] While the severity can range from mild to life-threatening, modern newborn screening programs now identify most cases shortly after birth, allowing for immediate management.

Recognizing the Symptoms

Symptoms of VLCAD deficiency can manifest at any age, from infancy to adulthood [1], and are often triggered by physiological stress. The presentation varies significantly based on the level of enzyme activity present in the individual's system.

Category

Common Symptoms

Metabolic

Severe low blood sugar (hypoglycemia), extreme fatigue, and lethargy. [1]

Physical

Muscle pain, weakness, poor feeding in infants, and vomiting.

Organ-Related

Enlarged liver (hepatomegaly), heart muscle disease, and irregular heart rhythms. [1]

It is important to note that many individuals with milder forms of the condition may remain asymptomatic until a trigger, such as a common cold or a long period of fasting, occurs. [1]

Illustration of VLCAD deficiency showing a fatty acid oxidation defect causing an energy crisis, with low energy, hypoglycemia and muscle pain, and involvement of the heart, liver and muscles. – rinnit.com

Causes and Risk Factors

The primary cause of VLCAD deficiency is a mutation in the ACADVL gene, which provides the instructions for creating the VLCAD enzyme. [1] This enzyme is essential for processing very long-chain fatty acids, which serve as a vital energy source for the heart and muscles. When the enzyme is insufficient or non-functional, these fats accumulate and can become toxic to tissues, while the body simultaneously starves for energy.

Because the condition is inherited in an autosomal recessive pattern, parents who each carry one mutated gene have a 25% chance of passing the condition to their child with each pregnancy. [1] Families with a history of metabolic disorders or those who have already had a child with VLCAD are at a higher risk.

Diagnosis and Clinical Testing

Diagnosis typically begins with newborn screening, where healthcare providers measure the levels of a specific blood marker known as C14:1. [1] If these levels are elevated, further diagnostic steps are required to confirm the condition and assess its potential severity.

  • Enzyme Activity Testing: This measures how effectively the VLCAD enzyme is working, which helps predict whether the condition will be mild or severe. [1] [4]

  • Genetic Testing: Analysis of the ACADVL gene can identify the specific mutations responsible for the deficiency. [1] [3]

  • Organ Function Tests: Echocardiograms and ECGs are used to monitor heart health [1], while blood tests assess liver function and glucose levels.

Flowchart of the VLCAD diagnostic pathway: newborn screening heel prick blood spot, laboratory analysis of C14:1 acylcarnitine markers, then ACADVL genetic testing for confirmation. – rinnit.com

Management and Treatment Strategies

Treatment for VLCAD deficiency is lifelong [1] and focuses on preventing metabolic crises by ensuring a steady supply of energy. The cornerstone of management is the avoidance of fasting, as the body must not be forced to rely on long-chain fats for fuel.

Management Pillar

Description

Dietary Control

A specialized low-fat, high-carbohydrate eating plan tailored to the individual's needs.

Frequent Feeding

Regular meals and snacks, especially for infants, to maintain stable blood sugar levels.

Supplements

Use of medium-chain triglyceride (MCT) oil, which the body can process without the VLCAD enzyme.

Medical Fat

FDA-approved options like triheptanoin may be prescribed under medical supervision. [1]

Healthcare providers also emphasize the importance of a "sick day plan." [1] During illness, the body's energy needs increase, and the risk of a metabolic crisis rises, often requiring hospital-based monitoring or intravenous glucose.

Infographic of VLCAD management strategies: a specialized low-fat diet with complex carbohydrates, MCT oil supplements, and a sick day plan with early medical help. – rinnit.com

Long-Term Outlook

The prognosis for individuals with VLCAD deficiency has improved dramatically with the advent of early screening and personalized care. Most people can expect a normal life expectancy [1] and high quality of life if they adhere to their management plan. Ongoing monitoring by metabolic specialists and cardiologists is essential to prevent long-term complications such as heart disease or chronic muscle issues.

Conclusion

VLCAD deficiency is a complex but manageable metabolic disorder. By understanding the triggers and adhering to a strict dietary and monitoring schedule, families can successfully navigate the challenges of the condition. Early diagnosis remains the single most important factor in ensuring a positive long-term outcome.

When to Seek Medical Care

If you or your child have been diagnosed with VLCAD, consult with a metabolic specialist to develop a personalized care plan. Consistent monitoring and early intervention during illness are key to maintaining long-term health.

Frequently Asked Questions

Is VLCAD deficiency common?

No, it is a rare genetic disorder, though it is one of the more common fatty acid oxidation disorders identified in newborn screening.

Can VLCAD be cured?

There is currently no genetic cure for VLCAD, but it can be highly effectively managed through diet and lifestyle adjustments.

What foods should be avoided with VLCAD?

Individuals may need to limit high-fat meats, fried foods, high-fat dairy, and certain oils rich in long-chain fats.

Can people with VLCAD exercise?

Yes, but exercise must be managed carefully. Physical activity increases energy demand, so individuals may need extra carbohydrates or MCT oil before and during activity.

What is a "metabolic crisis" in VLCAD?

A metabolic crisis occurs when the body runs out of energy and begins to break down muscle or accumulate toxic fats, leading to lethargy, vomiting, and potential organ failure.

How does newborn screening help?

Newborn screening identifies the condition before symptoms appear, allowing parents to start a management plan that prevents early life-threatening complications.

Is VLCAD deficiency the same as SIDS?

While undiagnosed metabolic disorders were historically linked to some cases of sudden infant death, modern screening has significantly reduced this risk.

Do adults need to continue treatment?

Yes, even if symptoms are mild, the risk of metabolic stress during severe illness or intense physical activity remains throughout life.

Can MCT oil help with VLCAD?

Yes, medium-chain triglycerides do not require the VLCAD enzyme for metabolism, providing a safe alternative energy source for the body.

Is genetic counseling recommended?

Absolutely. Genetic counseling helps families understand the inheritance patterns and the risks for future pregnancies.

What are the signs of low blood sugar in VLCAD?

Common signs include extreme sleepiness, irritability, shakiness, and a lack of energy.

References

  1. Cleveland Clinic. VLCAD (Very Long-Chain Acyl-CoA Dehydrogenase) Deficiency. Cleveland Clinic. Last updated February 24, 2026. https://my.clevelandclinic.org/health/diseases/vlcad-very-long-chain-acyl-coa-dehydrogenase-deficiency

  2. Gillingham MB, Heitner SB, Martin J, et al. Triheptanoin versus trioctanoin for long-chain fatty acid oxidation disorders: a double blinded, randomized controlled trial. J Inherit Metab Dis. 2017;40(6):831-843. PMID 28871440. https://doi.org/10.1007/s10545-017-0085-8

  3. Miller MJ, Burrage LC, Gibson JB, et al. Recurrent ACADVL molecular findings in individuals with a positive newborn screen for very long chain acyl-coA dehydrogenase (VLCAD) deficiency in the United States. Mol Genet Metab. 2015;116(3):139-145. PMID 26385305. https://doi.org/10.1016/j.ymgme.2015.08.011

  4. Olsson D, Barbaro M, Haglind C, et al. Very long-chain acyl-CoA dehydrogenase deficiency in a Swedish cohort: Clinical symptoms, newborn screening, enzyme activity, and genetics. JIMD Rep. 2022;63(2):181-190. PMID 35281659. https://doi.org/10.1002/jmd2.12268

Medical disclaimer

The information provided in this article is for educational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

Comments


bottom of page